


Dorzagliatin

Chemical Properties

CAS No. :	1191995-00-2
Formula:	C ₂₂ H ₂₇ ClN ₄ O ₅
Molecular Weight:	462.93
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Dorzagliatin (HMS5552) is a dual-acting glucokinase (GK) activator. It also improves glycaemic control and pancreatic β -cell function in type 2 diabetes.
Targets(IC50)	Glucokinase
In vivo	In diabetic rats, Dorzagliatin (low-dose 10 mg/kg, and high-dose 30 mg/kg; administered intragastrically; daily 8:00 AM for one month) shows a glucose-lowering effect on the glucose levels[2].

Solubility Information

Solubility	DMSO: 150 mg/mL (324.02 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.64 mM), Sonication is recommended. 10% DMSO+90% Saline: 10 mg/mL (21.6 mM), Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1602 mL	10.8008 mL	21.6015 mL
5 mM	0.432 mL	2.1602 mL	4.3203 mL
10 mM	0.216 mL	1.0801 mL	2.1602 mL
50 mM	0.0432 mL	0.216 mL	0.432 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zhu XX, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β -cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. *Diabetes Obes Metab.* 2018 Sep;20(9):2113-2120.

Wang P, et al. Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus. *J Diabetes Res.* 2017;2017:5812607.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481